The Lichtsteiner Foundation is a non-profit organization that focuses on supporting projects and initiatives in the fields of education, science, and culture. It aims to promote and develop these areas by providing financial assistance, expertise, and resources to selected projects.

Lichtsteiner Foundation

The Lichtsteiner Foundation invests in early stage start-ups (in Medtech, Life Science, Mental Health, Public Health and Wellbeing), to help pioneers bring their inventions to life. The Foundation focuses on impact investing by providing funding in the form of equity.

The purpose of the Lichtsteiner Foundation is to promote discoveries in the field of medicine for the improvement of people’s health around the world. The Lichtsteiner Foundation is a charitable, tax-exempt, independent foundation under Swiss law with its registered office in Berne and is subject to the supervision of the Federal Department of Internal Affairs.

The Foundation supports 1 – 5 start-ups in the early-stage phase every year – in other words no research projects – with a total value of CHF 1  million. It can work in Switzerland and internationally within the framework of its purpose; it does not seek a pecuniary gain or to make a profit. #foundation #startups #founders #profiling #impactinvesting #cofounding #health #medicaltechnology #biotechnology #lifescience #mentalhealth #publichealth #wellbeing

We at the Lichtsteiner Foundation would like to congratulate Marija Plodinec on her well-deserved award. Marija has won the first POWHER award for Hi-Tech Entrepreneur of the year. 

#hightechentrepreneur #ARTIDIS #LichtsteinerFoundation

We are excited to hear that MUVON Therapeutics AG has announced the enrollment of the first patient in their phase II clinical study. We wish them success in this next part of the process and look forward to learning more about the results of regenerative cell therapy to help women with stress urinary incontinence.
 
➡ To read the full press release: https://lnkd.in/ehQMr5wm
 
#LichtsteinerFoundation #MUVONTherapeutics #regenerativemedicine

We are delighted to announce that our team has grown - Welcome Alethia de Leon Egle B. Thomas, PhD MBA Céline Vuilleumier 🎉🎉

Click on the link to learn more about their unique personalities: https://lnkd.in/eCTznyD7  
#LichtsteinerFoundation #Team #Health #Startups

We at the Lichtsteiner Foundation would like to congratulate ARTIDIS on their new strategic alliance. We are looking forward to all the good that this alliance will bring. 

#ARTIDIS #LichtsteinerFoundation #nanotechnology

It is with great pleasure that we welcome Healios AG, its CEO and Co-Founder Guilhem Dupont and his team to the start-up community of the Lichtsteiner Foundation.

 Healios AG is a MedTech company that has worked with pharmaceutical companies and academic research teams in the EU and U.S. to develop and validate digital biomarkers. Healios AG has developed a smartphone technology that monitors the neurological functions of multiple sclerosis (MS) patients, called DreaMS™, CE Mark (Class I) in collaboration with the Research Centre for Clinical Neuroimmunology and Neuroscience of University Hospital Basel https://lnkd.in/e8XjverA
 
Healios AG Digital Biomarkers cover five key domains (movement, balance, dexterity, vision and cognition), and each domain can be measured through the performance of fun and interactive proprietary tests tailored to the research needs. The Healios AG technology meets requirements for CE Mark and FDA and has applications across neuroscience, cardiovascular and beyond.
#startup  #medtech  #research  #digitalbiomarkers  #biomarkers  #neuroscience

https://lnkd.in/eRniEaGx

Sabina Sperisen the CEO of the Lichtsteiner Foundation has been interviewed by Startupticker.ch.

We are delighted to announce our new Lichtsteiner Foundation testimonial video about MUVON Therapeutics AG Co-Founder and CEO Deana Mohr-Haralampieva, who is currently featured in Top 30 In Vivo’s Rising Leaders 2022 (https://lnkd.in/e4-HM2QM).

MUVON Therapeutics AG  develops an autologous cell therapy platform for the treatment of diseases related to skeletal muscle damage or degradation. Their goal is to help millions of patients suffering from stress urinary incontinence to regain control over their life by offering them minimally invasive, low-risk treatments for the regeneration of skeletal muscle tissue. #MUVONTherapeutics #precisionmedicine #regenerativetreatments #urinaryincontinence

Metric
Company Name	Lichtsteiner Foundation
Symbol
MSH ID	ORG:LICHTSTEINERFOUNDATION
Market	PRIVATE
Sector	Public & Social Sector
Industry	Non-profit / Philanthropy
Country	CH
Stage
Employee Count	7
Website	lichtsteinerfoundation.org
LinkedIn	lichtsteiner-foundation
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	43
Web Traffic Growth	-0.95
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ORG:LICHTSTEINERFOUNDATION

Lichtsteiner Foundation

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue